Liquid Biopsy Market Grows on Personalized
Oncology Demand and Non-Invasive Screening
Overview
13 June 2025 –The global liquid biopsy market is expected to grow significantly, rising from
USD 10.3 billion in 2023 to USD 35.3 billion by 2033, with a compound annual growth rate
(CAGR) of 13.1%. A major factor fueling this growth is the increasing global emphasis on
early cancer detection. Organizations such as the World Health Organization (WHO) and
national health bodies are actively promoting early diagnostics to improve patient outcomes.
Liquid biopsy—an innovative blood test—offers a quick, minimally invasive way to detect
cancer, making it more accessible than traditional tissue biopsies.
The rising preference for non-invasive diagnostic tools is further accelerating market
adoption. Unlike conventional surgical biopsies, liquid biopsies are safer, more comfortable,
and better suited for patients with hard-to-reach tumors or those unable to undergo surgery.
Countries like the U.S. and the U.K. are actively supporting this shift through healthcare
policies and funding initiatives that encourage the use of patient-friendly diagnostic solutions.
Government backing and public health initiatives are also vital contributors to market
expansion. Many nations have launched pilot programs and allocated resources to integrate
liquid biopsy into standard medical care. Increasing insurance coverage for these tests is
helping reduce financial barriers, making it easier for both providers and patients to embrace
this advanced diagnostic method.
Technological innovation is another key growth driver. Advanced platforms are now capable
of detecting minuscule fragments of tumor DNA in the bloodstream, enhancing the accuracy
of early cancer detection. Agencies like the National Cancer Institute are supporting research
to refine these technologies, which are also proving useful in monitoring treatment progress
in real time. This functionality is crucial for personalized medicine, where continuous updates
guide therapy adjustments.
Emerging markets across Asia, Africa, and Latin America are also contributing to the
market’s upward trajectory. With expanding healthcare infrastructure and growing
investment in modern screening programs, liquid biopsy is becoming a standard part of
cancer diagnostics in major hospitals. Moreover, interest in multi-cancer early detection
(MCED) tests—which can identify multiple cancers from a single blood sample—is on the
rise. As global healthcare systems continue to modernize and public-private partnerships
drive innovation, the liquid biopsy market is well-positioned for sustained growth in the years
ahead.
Key Takeaways








The global liquid biopsy market was valued at about USD 10.3 billion in 2023 and
may hit USD 35.3 billion by 2033.
This market is expanding rapidly, expected to grow at a strong CAGR of 13.1%
throughout the forecast period from 2023 to 2033.
Multi-Gene-Parallel Analysis (NGS) dominated in 2023, accounting for
approximately 72.8% of the overall technology market share.
Circular Nucleic Acids played a big role in 2023, contributing over 34.78% of total
revenue among liquid biopsy biomarkers.
Instruments were key revenue drivers in 2023, with nearly 44.9% of the total market
share attributed to them alone.
Around 77% of the liquid biopsy market in 2023 was focused on the detection and
diagnosis of various cancer types.
Hospitals and laboratories held a significant share, jointly owning over 47.2% of the
market revenue in 2023.
North America led the global market in 2023, contributing more than 47.1% of
overall liquid biopsy revenues.
Get sample report : https://market.us/report/liquid-biopsy-market/request-sample/
Emerging Trends
Rising Demand for Non-Invasive Testing
Hospitals and clinics are increasingly using liquid biopsy. The main reason is that it requires
only a simple blood draw. This makes it much safer than traditional tissue biopsies, which
often need surgery. For very sick patients or those with tumors in hard-to-reach areas, this
method is a relief. It also reduces the risk of infection, pain, and recovery time. As more
people prefer less invasive testing, liquid biopsy is quickly becoming the go-to choice. This
shift is making it easier to detect diseases early while improving the overall patient
experience.
Broadening Scope Beyond Cancer
Liquid biopsy started as a tool to detect and manage cancer. But its uses are now expanding
fast. Doctors are exploring it to monitor organ transplant rejection. It’s also being studied for
use in prenatal screening and early signs of brain disorders. This wider range of applications
shows the huge potential of the technology. It can offer real-time insights into multiple health
conditions. As research grows, liquid biopsy could become a regular part of diagnosis beyond
oncology. This makes it one of the most flexible tools in modern medicine.
Advanced Biomarker Discovery
Scientists are now looking at more types of biomarkers in blood samples. These include
exosomes, microRNA, and circulating tumor cells. Each offers unique clues about how a
disease is developing. Some can even tell how well a treatment is working. This helps doctors
make faster and smarter treatment decisions. Advanced biomarker discovery means liquid
biopsy is no longer just about finding cancer. It’s about understanding diseases at a much
deeper level. These insights are helping create highly personalized treatment plans for
patients.
Conclusion
The liquid biopsy market is growing fast, driven by the global need for early, accurate, and
less invasive cancer detection. More hospitals and health systems are adopting this method
because it offers real-time insights and improves patient comfort. Government support, new
technologies, and rising awareness are all pushing the market forward. Liquid biopsy is not
only useful for diagnosis but also for monitoring treatment and detecting recurrence. Its
growing role in personalized medicine shows how important it is becoming in modern
healthcare. With wider applications beyond cancer and support from both public and private
sectors, liquid biopsy is set to become a key part of future diagnostic practices worldwide.
Contact us on
Market.us (Powered By Prudour Pvt. Ltd.)
Email: inquiry@market.us
Address: 420 Lexington Avenue, Suite 300,
New York City, NY 10170, United States
Tel: +1 718 618 4351